Literature DB >> 30410214

Benralizumab for asthma.

.   

Abstract

Entities:  

Keywords:  Fasenra; asthma; benralizumab

Year:  2018        PMID： 30410214      PMCID： PMC6202302          DOI： 10.18773/austprescr.2018.051

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  4 in total

1.  Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.

Authors:  J Mark FitzGerald; Eugene R Bleecker; Andrew Menzies-Gow; James G Zangrilli; Ian Hirsch; Paul Metcalfe; Paul Newbold; Mitchell Goldman
Journal:  Lancet Respir Med       Date:  2017-09-11       Impact factor: 30.700

2.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.

Authors:  Eugene R Bleecker; J Mark FitzGerald; Pascal Chanez; Alberto Papi; Steven F Weinstein; Peter Barker; Stephanie Sproule; Geoffrey Gilmartin; Magnus Aurivillius; Viktoria Werkström; Mitchell Goldman
Journal:  Lancet       Date:  2016-09-05       Impact factor: 79.321

3.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  J Mark FitzGerald; Eugene R Bleecker; Parameswaran Nair; Stephanie Korn; Ken Ohta; Marek Lommatzsch; Gary T Ferguson; William W Busse; Peter Barker; Stephanie Sproule; Geoffrey Gilmartin; Viktoria Werkström; Magnus Aurivillius; Mitchell Goldman
Journal:  Lancet       Date:  2016-09-05       Impact factor: 79.321

4.  Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.

Authors:  Parameswaran Nair; Sally Wenzel; Klaus F Rabe; Arnaud Bourdin; Njira L Lugogo; Piotr Kuna; Peter Barker; Stephanie Sproule; Sandhia Ponnarambil; Mitchell Goldman
Journal:  N Engl J Med       Date:  2017-05-22       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.